Screener
Acadia Pharmaceuticals ACAD Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 6, 2026, 8:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-209731
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Maturity of investment securities | 86,500 | 130,800 |
| Payment of milestone and contingent payments in connection with asset acquisition | — | (98,838) |
| Purchases of property and equipment | (5,212) | — |
| Net cash provided by (used in) investing activities | 66,281 | (124,049) |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock, net of issuance costs | 4,231 | 1,838 |
| Net cash provided by financing activities | 4,231 | 1,838 |
| Effect of exchange rate changes on cash | 25 | (5) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Acadia Pharmaceuticals's investing cash flow?
- Acadia Pharmaceuticals (ACAD) reported investing cash flow of $66.28M in Q1 2026.
- How has Acadia Pharmaceuticals's investing cash flow changed year-over-year?
- Acadia Pharmaceuticals's investing cash flow increased by 153.4% year-over-year, from -$124.05M to $66.28M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Acadia Pharmaceuticals's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude